---
schema_version: "secwatch.filing_event.v1"
accession: "0001737287-23-000083"
form_type: "8-K/A"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2023-10-17T23:59:59+00:00"
generated_at: "2026-06-09T22:42:09.295601+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Allogene appoints Geoffrey Parker as CFO with $490K salary and equity grants

## Summary
- Geoffrey Parker appointed EVP, CFO, Principal Financial and Accounting Officer effective Oct 16, 2023.
- Replaces David Chang and Jack Chen as interim principal financial and accounting officers.
- Prior roles: COO/CFO of Tricida, CFO of Anacor (acquired by Pfizer for $5.2B), MD at Goldman Sachs.
- Compensation: $490K base salary, 45% target bonus, stock option for 950K shares, RSU for 400K shares.
- Performance RSU of 390K shares vests upon $18.00 share price or first FDA product approval by 2026/2028.

## SEC filing metadata
- accession: 0001737287-23-000083
- form_type: 8-K/A
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2023-10-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000173728723000083/0001737287-23-000083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000173728723000083/allo-20231016.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001737287-23-000083
- JSON: https://secwatch.observer/filing/0001737287-23-000083.json
- Plain text: https://secwatch.observer/filing/0001737287-23-000083.txt

## Key facts
- Executive change
  Geoffrey Parker was appointed as Executive Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer at Allogene Therapeutics, Inc..
  - Action: appointed
  - Role: Executive Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer
  source text: appointed Geoffrey Parker as the Company’s Executive Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer effective October 16, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737287/000173728723000083/0001737287-23-000083-index.htm
- Executive change
  David M. Chang changed role as Interim Principal Financial Officer at Allogene Therapeutics, Inc..
  - Action: replaced
  - Role: Interim Principal Financial Officer
  source text: replacing David M. Chang, M.D., Ph.D. and Jack Chen in their capacities as the Company’s interim principal financial officer and interim principal accounting officer, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737287/000173728723000083/0001737287-23-000083-index.htm
- Executive change
  Jack Chen changed role as Interim Principal Accounting Officer at Allogene Therapeutics, Inc..
  - Action: replaced
  - Role: Interim Principal Accounting Officer
  source text: replacing David M. Chang, M.D., Ph.D. and Jack Chen in their capacities as the Company’s interim principal financial officer and interim principal accounting officer, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737287/000173728723000083/0001737287-23-000083-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.